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OBJECTIVES The study examined the frequency, correlates, and outcome of patients with stent thrombosis
within 30 days of stent placement.
BACKGROUND Patients in trials evaluating stents or dual antiplatelet therapy to prevent coronary stent
thrombosis have generally had narrow inclusion criteria; the extent to which stent thrombosis
rates in such trials represent current practice, particularly with the availability of newer stents,
is unclear.
METHODS We performed a retrospective analysis of the Mayo Clinic Percutaneous Coronary Interven-
tion database and identified all patients who received at least one coronary stent and dual
antiplatelet therapy (aspirin and ticlopidine or clopidogrel for two to four weeks).
RESULTS Four thousand five hundred nine patients underwent successful coronary stent implantation
and were treated with dual antiplatelet therapy between July 1, 1994, and April 30, 2000.
Stent thrombosis occurred in 23 patients (0.51%; 95% confidence interval 0.32%, 0.76%)
within 30 days of stent placement. Multivariate analysis using bootstrap model selection to
avoid over-fitting the model indicated that only the number of stents placed was an
independent correlate of stent thrombosis (odds ratio 1.80, p  0.001). The frequency of
death and frequency of nonfatal myocardial infarction (MI) among the 23 patients with stent
thrombosis were 48% and 39%, respectively.
CONCLUSIONS Stent thrombosis is even more rare in the current era than in earlier trials. Number of stents
placed was an independent correlate of stent thrombosis. Most patients who suffer stent
thrombosis either die or suffer MI. (J Am Coll Cardiol 2002;40:1567–72) © 2002 by the
American College of Cardiology Foundation
Five randomized, controlled trials have established the
superiority of dual antiplatelet therapy with aspirin and a
thienopyridine when compared with aspirin alone, or aspirin
and warfarin, in preventing stent thrombosis after percuta-
neous coronary intervention (PCI) and stent placement
(1–5). However, the frequency of stent thrombosis differed
significantly between these trials. Furthermore, these trials
applied strict inclusion and exclusion criteria, and the
frequency of stent thrombosis in such trials may not accurately
reflect the frequency of stent thrombosis in current clinical
practice. Presently, the use of ticlopidine has been replaced by
clopidogrel, and different stents are used from those utilized in
the randomized trials; therefore, the frequency of stent throm-
bosis may differ from that seen in the prior trials.
We sought to determine the frequency and timing of
stent thrombosis and other adverse events occurring within
the first 30 days after coronary stent placement.
METHODS
We performed a retrospective analysis of the Mayo Clinic
PCI database and identified all patients who received at
least one coronary stent and dual antiplatelet therapy. This
computerized database includes prospectively collected
baseline, procedural, and angiographic data on all patients
undergoing PCI at the Mayo Clinic, Rochester, Minnesota.
The indications for PCI included stable angina (elective
procedures), unstable angina, and acute myocardial infarc-
tion (MI) (urgent and emergency procedures).
Angiographic, procedural, and clinical outcomes were
recorded prospectively on line by experienced interventional
cardiology or coronary care unit nurses before the patient’s
dismissal. All patients were contacted at 6 months, 12
months, and yearly thereafter by a clinical research nurse,
according to a protocol approved by the Mayo Foundation
Institutional Review Board. Medical records of all patients
requiring hospitalization at the Mayo Clinic and elsewhere
were reviewed to further characterize any clinical events
during the study period. This study was approved by the
Mayo Clinic Institutional Review Board.
Inclusion and exclusion criteria. All patients were in-
cluded in this analysis if they had undergone successful
deployment of at least one coronary stent without the
occurrence of a major in-lab complication (death, Q-wave
MI, emergency cardiac surgery, cerebrovascular accident,
transient ischemic attack, coronary perforation, or develop-
ment of cardiogenic shock). Patients were excluded if there
was intent not to administer aspirin or a thienopyridine, if
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they were in cardiogenic shock before the procedure, if
brachytherapy was administered, if coumadin was adminis-
tered prior to discharge from the hospital after the index
procedure, if an experimental fibrin-coated stent was used, if
the patient experienced stent thrombosis after 30 days post
PCI, or if the patient refused permission for his or her
records to be used for research (as required by Minnesota
state law). If patients underwent more than one qualifying
procedure during the study period, only the first stent
procedure was analyzed.
Antiplatelet regimens. All patients received 325 mg of
aspirin before intervention and every day thereafter. A
500-mg loading dose of ticlopidine was administered orally
immediately before the procedure, after which ticlopidine,
250 mg twice daily, was administered for four weeks. From
1996 onward, ticlopidine was administered for only two
weeks (6). Since September 1998, clopidogrel administered
as a 300 mg loading dose immediately before the procedure,
followed by 75 mg/day for two or four weeks, was used
instead of ticlopidine (7). Heparin was administered on a
weight-adjusted basis immediately before the procedure,
with an aim for an activated clotting time (ACT) of
approximately 300 s (initial dose, 100 U/kg) when a
glycoprotein IIb/IIIa inhibitor was not used and approxi-
mately 250 s when a glycoprotein IIb/IIIa was given (initial
dose, 70 U/kg). The ACT was generally remeasured every
30 to 60 min during the procedure, and additional boluses
of heparin were given to maintain the ACT in the target
range. Heparin was almost invariably discontinued at the
end of the procedure, although in very rare instances at the
operator’s discretion it was continued for up to 24 h in
selected high-risk patients. The decision to use a glycopro-
tein IIb/IIIa inhibitor was made by the cardiologist per-
forming the procedure, who considered clinical and angio-
graphic features of the patient and avoided the use of a
glycoprotein IIb/IIIa inhibitor if contraindications were
apparent.
PCI technique. Coronary angioplasty and intracoronary
stent implantation were performed after standard PCI
techniques and as previously described (8). Delivery bal-
loons were inflated to nominal pressure. Throughout the
study period (July 1, 1994, to April 30, 2000), stent delivery
has been routinely followed by high-pressure (14 atm)
balloon inflations using noncompliant or minimally compli-
ant balloons at sizes equivalent to or slightly larger than
nominal stent size to achieve residual diameter stenosis
20% without intraluminal filling defects. Intravascular
ultrasound was performed at the discretion of the operator.
Definitions. Successful stent placement was defined as a
residual stenosis within the stented segment of 50% by
visual estimation and the ultimate achievement of Throm-
bolysis In Myocardial Infarction (TIMI) flow grade 3. Stent
thrombosis was considered to have occurred when con-
firmed angiographically (intraluminal filling defect within
the stent resulting in TIMI grade 0 or 1 anterograde blood
flow), when death was sudden and unexplained, or when an
MI (both ST-segment elevation and non–ST-segment ele-
vation MI) occurred in the territory of the treated vessel and
stent thrombosis could not be excluded definitively.
Follow-up. All patients were contacted via telephone or
mail using a standardized questionnaire at 6 months, 12
months, and then yearly after their procedure. All adverse
events were confirmed by reviewing the medical records of
patients followed up at our institution and by contacting the
patients’ physicians and obtaining and reviewing the hospi-
tal records of patients followed up elsewhere.
Statistical analysis. Data are presented as percentages, and
means as  1 SD. Comparisons between groups are made
using one-way analysis of variance or the Pearson chi-square
test. Confidence intervals for event rates are calculated using
exact binomial algorithms. A multiple logistic regression
model for early stent thrombosis was developed using
bootstrap selection methods (to avoid an overfit model).
Twenty-one variables that correlated with early stent
thrombosis at the 0.15 significance level comprised the full
model. (The cutoff of 0.15 was chosen because variables may
be significant in a multiple regression model but not in a
simple regression model.) Two hundred bootstrap samples
were selected; stepwise selection of the 21 variables was
applied to each sample. The final model consisted only of
variables selected in at least 140 (70%) of the bootstrap
models (9). Analyses were performed using SAS software
(SAS Inc., Cary, North Carolina).
RESULTS
Patient population. Four thousand six hundred five pa-
tients underwent PCI with successful coronary stent im-
plantation and were treated with dual antiplatelet therapy
between July 1, 1994, and April 30, 2000, constituting
approximately 50% of all the PCI procedures at the Mayo
Clinic, Rochester, Minnesota, in that time period. The
most common reason for exclusion from the database was
balloon angioplasty treatment without adjunctive stenting
(30%). Eighty-six patients (1.9%) refused permission for
their records to be used for research. Twenty-three patients
developed stent thrombosis within 30 days of stent place-
ment (0.51%, 95% confidence interval [CI] 0.32%, 0.76%).
Of the patients included in this analysis, all but one
(99.98%) were contacted, and their clinical status reviewed.
The analysis includes the 4,508 patients who gave permis-
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sion for their records to be used for research and who were
contacted; patients refusing permission for their data to be
analyzed were excluded, as is required by Minnesota law.
Baseline clinical characteristics. The mean age of the
patients (13 men, 10 women) who developed stent throm-
bosis was 69.6  15.2 years (Table 1). These patients had a
higher incidence of congestive heart failure (CHF) on
presentation and were more likely to have a past medical
history of CHF or metastatic cancer (p  0.05) than
patients who did not develop stent thrombosis.
Baseline angiographic and procedural characteristics.
Univariate predictors (Table 2) of stent thrombosis included
left main PCI, number of stents placed, number of segments
treated, minimum stent diameter, calcium in any stenosis,
American Heart Association type C lesion characteristics,
and angiographic evidence of plaque ulceration (p  0.05).
However, the large majority of patients with these charac-
teristics did not develop stent thrombosis.
Multivariate analysis. Multivariate analysis using boot-
strap model selection identified the number of stents placed
(selected in 84.5% of bootstrap samples) as an independent
correlate of stent thrombosis (odds ratio [OR] 1.80, p 
0.001). No other covariate was selected in more than 70% of
the samples. When adjusted for number of stents in separate
logistic models, CHF on presentation (OR 3.4, p  0.03),
concentric lesions (OR 3.0, p  0.03), ulcerated lesions
(OR 2.8, p  0.03), history of CHF (OR 2.9, p  0.04),
and metastatic cancer (OR 7.9, p  0.05) were significantly
correlated with stent thrombosis (Table 3). These five
variables could be considered good candidates for also being
independently correlated with stent thrombosis. Indeed,
they were significantly correlated with stent thrombosis in
our patients. However, the bootstrap analysis indicates that
these relationships may be specific to this patient population.
Clinical outcomes. The frequency of death and nonfatal
MI among the 23 patients with stent thrombosis was 48%
(95% CI 27%, 69%) and 39% (95% CI 20%, 61%), respec-
tively. The rate of nonfatal ST-elevation or Q-wave MI was
30% (95% CI 13%, 53%). One patient (4%; 95% CI 0.1%,
22%) was identified on the basis of diagnostic angiography
alone.
The incidences of death and nonfatal MI within 30 days
of stent placement among the 4,508 study patients were
0.8% (n 38; 95% CI 0.6%, 1.2%) and 4.9% (n 241; 95%
CI 4.3%, 5.5%), respectively.
Control group. Among patients without stent thrombosis
in the 30 days after their PCI procedure, the one-year
Kaplan-Meier mortality rate was 3.1%, the non-fatal MI
rate was 7.1%, and the combined death or non-fatal MI rate
was 10.1%. The rate of repeat PCI of the treated vessel (in
patients alive at one year and free of MI) was 8.1%, and the
rate of coronary artery bypass graft surgery was 4.9%. The






(n  23) p Value
Age (yrs) 65.4  11.7 69.6  15.2 0.08
Male gender 3,190 (71) 13 (57) 0.12
Body mass index (kg/m2) 29.1  5.3 27.4  5.2 0.13
Prior MI 2,207 (50) 14 (61) 0.29
Prior PTCA 1,050 (23) 9 (39) 0.08
Prior CABG 848 (19) 6 (26) 0.38
Current/former smoker 2,862 (65) 17 (74) 0.35
Current smoker 858 (19) 7 (30) 0.18
History of hypercholesterolemia 2,676 (66) 13 (62) 0.68
History of hypertension 2,680 (61) 15 (65) 0.68
Diabetes mellitus 941 (21) 6 (26) 0.56
CHF on presentation 279 (6) 4 (17) 0.028
History of CHF 449 (10) 5 (24) 0.040
CVA/TIA 429 (10) 3 (13) 0.58
Peripheral vascular disease 452 (10) 5 (22) 0.07
Unstable angina 3,051 (68) 13 (57) 0.24
Canadian heart class (III, IV) 2,457 (55) 10 (43) 0.28
Thrombolytic within 1 day 120 (3) 0 (0) 0.43
Thrombolytic within 2 days 159 (4) 0 (0) 0.36
MI within the prior 24 h 406 (9) 3 (13) 0.49
MI within 1 to 7 days 643 (14) 4 (17) 0.68
Metastatic cancer 31 (1) 1 (4) 0.038
Tumor/lymphoma/leukemia 398 (9) 3 (13) 0.49
Cardiac arrest pre-procedure 12 (1) 0 (0) 0.80
Moderate/severe renal disease 130 (3) 2 (9) 0.10
Continuous variables are presented as mean values  SD.
CABG  coronary artery bypass graft; CHF  congestive heart failure; CVA  cerebrovascular accident; MI  myocardial
infarction; PTCA  percutaneous transluminal coronary angioplasty; TIA  transient ischemic attack.
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estimated rate of the composite end point of any major
adverse cardiac events (death, non-fatal MI, or target lumen
revascularization) was 19.4%.
DISCUSSION
This study demonstrates that stent thrombosis in the
current era of improving stent design and construction and
dual antiplatelet therapy is even lower than previously
reported in most randomized trials and registry studies.
Also, although a number of correlates of stent thrombosis
were identified, most patients with these characteristics do
not experience stent thrombosis. Most patients who do
experience stent thrombosis, however, either die or suffer an
ST-elevation or Q-wave MI.
Rationale for the use of dual antiplatelet therapy.
Ticlopidine and clopidogrel are thienopyridine derivatives
that inhibit platelet aggregation by irreversibly inhibiting
the binding of adenosine diphosphate (ADP) to one of
three identified ADP receptors, the P2Y12 receptor, which
limits binding of fibrinogen to the glycoprotein IIb/IIIa
receptor complex (10). Platelet aggregation in response to
collagen, thrombin, and shear stress, all putative factors in
the pathogenesis of stent thrombosis, are also inhibited.
Incidence of stent thrombosis. The initial randomized
clinical trials comparing stent implantation with balloon
angioplasty revealed improved angiographic and, in one
study, clinical outcomes (11,12). This was achieved at the
cost of an increase in bleeding complications as a result of
the use of aggressive anticoagulation regimens following






(n  23) p Value
Vessel treated
Left anterior descending 1,986 (44.3) 14 (61) 0.11
Left circumflex 1,201 (27) 7 (30) 0.69
Right 1,651 (37) 7 (30) 0.53
Vein graft intervention 377 (8) 2 (9) 0.96
Any graft intervention 418 (9) 2 (9) 0.92
Left main 81 (2) 2 (9) 0.014
Total number of vessels treated 1.2  0.4 1.3  0.5 0.05
Maximum lesion length 1.9  0.7 2.2  1.6 0.06
Initial TIMI flow* 0.79
0 464 (10) 2 (7)
1 228 (5) 0 (0)
2 567 (12) 5 (19)
3 3,440 (73) 20 (74)
Total stents placed (no.) 1.6  0.9 2.4  1.4 0.001
Segments treated (no.) 1.6  0.8 2.0  1.0 0.003
Multivessel disease (70/70) 2,157 (50) 15 (65) 0.15
Complete revascularization 2,590 (58) 9 (39) 0.07
Maximum stent diameter 3.4  0.5 3.4  0.6 0.96
Maximum balloon diameter 3.4  0.6 3.4  0.6 0.91
Minimum stent diameter 3.2  0.5 3.0  0.5 0.049
Calcium in any stenosis 1,741 (41) 14 (64) 0.033
Maximum inflation pressure in stent 9.9  4.0 10.8  4.5 0.27
B2/C type lesion 3,464 (82) 20 (87) 0.51
Residual stenosis (%)* 6.6  15 8.3  20 0.41
C type lesion 1,882 (44) 17 (74) 0.004
Ulcer in any lesion 498 (12) 6 (29) 0.023
Thrombus in any lesion 1,288 (31) 5 (23) 0.42
TIMI grade 0 flow in any lesion pre-procedure 411 (14) 2 (17) 0.78
Dilation on severe bend 298 (7) 2 (9) 0.74
Dilation on moderate/severe bend 1,844 (43) 8 (35) 0.43
Any lesion ostial 769 (22) 5 (33) 0.28
Eccentric in any lesion 3,272 (83) 14 (70) 0.11
Major branch involvement 891 (21) 7 (33) 0.16
Minor branch involvement 1,573 (37) 11 (50) 0.20
Bifurcation lesion 556 (13) 3 (14) 0.93
Ejection fraction, % 57.8  15 56.3  10 0.74
Ejection fraction 40% 383 (9) 1 (4) 0.47
Glycoprotein IIb/IIIa use 1,800 (76) 13 (72) 0.70
Abciximab use 1,674 (38) 10 (43) 0.56
*Denominator is number of treated lesions.
TIMI  Thrombolysis In Myocardial Infarction.
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stent implantation. However, despite such therapy, stent
thrombosis rates were approximately 3.5% and associated
with significant morbidity and mortality. The routine use of
high-pressure stent deployment and dual antiplatelet ther-
apy, including a thienopyridine derivative, led to large
reductions in the incidence of this highly morbid compli-
cation (13,14). Subsequent registries and randomized con-
trolled trials have documented even lower rates of stent
thrombosis (0.5% to 1.9%) and a much lower risk of
bleeding than was seen with the prolonged use of heparin
while coumadin was being initiated (2–5,15–17). However,
these clinical trials generally had narrow inclusion criteria,
and the extent to which these trials reflect current clinical
practice is unclear. The true frequency of stent thrombosis
may also be influenced by substantial improvements in stent
designs, potentially rendering the earlier trial and registry
data outdated.
The current study. This study documents a very low rate
of stent thrombosis in a large, contemporary (years 1995 to
2000) cohort of patients treated with dual antiplatelet
therapy in which improved stent technology and interven-
tional techniques were available and utilized. This low rate
of stent thrombosis occurred despite the presence of many
clinical and angiographic risk factors previously associated
with higher frequencies of stent thrombosis. Even among
patients with these adverse characteristics, the frequency of
stent thrombosis was very low.
Risk factors for stent thrombosis. A number of risk
factors for stent thrombosis have been identified by previous
investigators. Persistent dissection, longer stent length, and
final lumen diameter within the stent were identified as
independent multivariable predictors of stent thrombosis in
a meta-analysis of 6,186 patients enrolled in six major
clinical trials of coronary stenting (17). Other studies have
identified balloon size 2.5 mm, bail-out situations, unsta-
ble angina or acute MI (15), ejection fraction, use of a
combination of different stents, postprocedural dissections,
and slow flow (16) as predictive of stent thrombosis.
Multivariate analysis of correlates of stent thrombosis is
difficult to perform in even a study as large as this because of
the low incidence of the primary end point. A common
method of avoiding over-fitting is bootstrap model selec-
tion. It involves creating random data sets from the patient
population, selecting correlates with stepwise model selec-
tion for each bootstrap sample, and counting the number of
patients in which a correlate was selected. Typically, any
correlate selected in at least 70% of patients is chosen for the
final model. The only variable that was selected at least 70%
of the time was the number of stents placed. Therefore, the
only variable for which we have strong evidence of an
association with early (30 days) stent thrombosis is number
of stents placed. When adjusted for number of stents, CHF,
ulcerated lesions, body mass index (per 5 kg/m2), and
metastatic cancer were also significant correlates of stent
thrombosis.
Clinical outcome of stent thrombosis. The clinical con-
sequences of stent thrombosis are generally severe. Mortal-
ity has generally been reported to exceed 20%, and the
combined end point of death and nonfatal MI exceeds 70%
(11,15–17). Although stent thrombosis in patients on dual
antiplatelet therapy typically occurs early and in the hospital,
poor clinical outcomes, despite successful percutaneous
restoration of flow, are common (8). Furthermore, six-
month outcomes among survivors of stent thrombosis are
not favorable, with mortality rates in the range of 20% to
25% (17). Mortality following stent thrombosis was partic-
ularly high (48%) in our registry. It is possible that this
resulted from our characterizing unexplained death as pre-
sumptive stent thrombosis; some such deaths could have
been due to arrhythmia, for example. Nonfatal MI occurred
in 39% of the patients with stent thrombosis. However,
these results are consistent with other studies in noting the
significant morbidity and mortality associated with this
increasingly rare complication of stent implantation.
Study limitations. First, subclinical stent thrombosis may
have occurred in some patients and been totally undetected.
It is also possible that over-diagnosis of stent thrombosis
may have occurred due to the fact that we characterized all
unexplained death as presumptive stent thrombosis, as
discussed above. However, this methodology is common to
most studies (randomized and observational) of stent
thrombosis and is thought to reflect the incidence of the
most clinical relevant outcomes of this complication (17,18).
Second, in this study we have analyzed the frequency of
stent thrombosis within 30 days; late stent thrombosis also
occurs, and was not analyzed in this study. Again, this
methodology is common to most studies of stent thrombo-
sis, and late stent thrombosis (30 days) is typically dealt
with as a distinct clinical entity (19,20). Third, these data
were collected by relying on patient interview, and therefore
recall bias must be considered as a possible confounding
factor. Finally, one patient was lost to follow-up; however,
even if this patient had suffered stent thrombosis, the
findings of this study would not change significantly.
Conclusions. Stent thrombosis in the first 30 days after
stent placement and treatment with aspirin and a thienopy-
ridine is rare in clinical practice, occurring in 0.5% of
Table 3. Adjusted Odds Ratios for Early Stent Thrombosis
Variable Odds Ratio p Value
CHF on presentation 3.44 0.027
Concentric geometry in any lesion 3.02 0.030
Ulcer in any lesion 2.81 0.033
History of CHF 2.92 0.039
Metastatic cancer 7.91 0.048
AHA/ACC C type lesion 2.61 0.052
Left main intervention 4.29 0.053
Age (in decades) 1.43 0.063
Peripheral vascular disease 2.57 0.065
Female gender 2.04 0.095
Incomplete revascularization 2.02 0.102
ACC  American College of Cardiology; AHA  American Heart Association;
CHF  congestive heart failure.
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patients despite many clinical and angiographic risk factors
previously associated with high frequencies of stent throm-
bosis. However, when stent thrombosis occurs, the majority
of patients either die (48%) or have a nonfatal MI (39%).
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